Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CCR10 | P46092 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182004 | 1.00 | OPRK1 (0.39) | OPRK1HRH2HRH1PARK7MARK3 | |
| SCHEMBL181748 | 0.89 | HRH2 (0.42) | OPRK1HRH2HRH1MARK3OPRD1 | |
| SCHEMBL182063 | 0.89 | HRH2 (0.42) | OPRK1HRH2HRH1MARK3OPRD1 | |
| SCHEMBL181749 | 0.89 | HRH2 (0.42) | OPRK1HRH2HRH1MARK3OPRD1 | |
| Hydrochloric Acid SCHEMBL181827 | 0.88 | HRH2 (0.41) | OPRK1HRH2HRH1MARK3OPRD1 | |
| Hydrochloric Acid SCHEMBL181828 | 0.88 | HRH2 (0.41) | OPRK1HRH2HRH1MARK3OPRD1 | |
| SCHEMBL182015 | 0.87 | CCKBR (0.43) | PARK7MARK3MEN1KMT2ACCR10 | |
| SCHEMBL182152 | 0.82 | PABPC1 (0.47) | HRH2HRH1KMT2A | |
| SCHEMBL182153 | 0.82 | PABPC1 (0.47) | HRH2HRH1KMT2A | |
| SCHEMBL181673 | 0.82 | CCKBR (0.38) | MARK3CCR10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401268-B1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8697877-B2 | Oxyindole derivatives with motilin receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2401268-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | OPRK1 26/4885HRH2 222/4885HRH1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.